首页 > 神经医学词汇大全 > Methotrexate
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.
Tocilizumab 或阿达木单抗或甲氨蝶呤单药治疗的类风湿关节炎临床试验中,同时招募患者进行糖皮质激素治疗对疗效和安全性试验结果的影响。
DMARDs (biologic) corticosteroids outcomes research rheumatoid arthritis
下载

摘要

BACKGROUND:In rheumatoid arthritis (RA) trials, inclusion of patients on background treatment with glucocorticoids (GCs) might impact efficacy and safety outcomes.
OBJECTIVES:To determine if inclusion of patients on background GC use influenced efficacy and safety outcomes of RA randomised clinical trials on initiation of tocilizumab (TCZ) or adalimumab (ADA) or methotrexate (MTX) monotherapy.
METHODS:Data of four double-blind RA randomised controlled trials (AMBITION, ACT-RAY, ADACTA and FUNCTION) with in total four TCZ, one ADA and two MTX monotherapy arms were analysed. Analyses of covariance of changes from baseline to week 24 in efficacy endpoints and radiographic progression up to week 104 were performed, correcting for relevant covariates. Incidence rates of serious adverse events (SAEs) were assessed.
RESULTS:No statistically significant differences were found in efficacy parameters between background GC users and non-GC users, except for less radiographic progression associated with GC usage in one MTX arm. SAE rates were not statistically significantly different between GC users and non-GC users in the treatment arms.
CONCLUSION:No effect of including patients on background GC treatment on efficacy and safety trial outcomes was found, with the exception of reduced radiological joint damage in one MTX arm.

译文

背景: 在类风湿关节炎 (RA) 试验中,纳入糖皮质激素 (GCs) 背景治疗的患者可能会影响疗效和安全性结果。
目的: 确定纳入背景 GC 使用的患者是否会影响开始使用托珠单抗 (TCZ) 或阿达木单抗 (ADA) 或甲氨蝶呤 (MTX) 的 RA 随机临床试验的疗效和安全性结果单一疗法。
方法: 分析四项双盲 RA 随机对照试验 (amerition 、 ACT-RAY 、 ADACTA 和 FUNCTION) 的数据,总共有四个 TCZ 、一个 ADA 和两个 MTX 单药治疗组。进行了从基线到 24 周疗效终点变化的协方差分析,以及到 104 周的影像学进展,纠正了相关的协变量。评估严重不良事件 (SAEs) 的发生率。
结果: 背景 GC 使用者和非 GC 使用者之间的疗效参数没有发现统计学上的显著差异,除了在一个 MTX 组中与 GC 使用相关的影像学进展较少。在治疗组中,GC 使用者和非 GC 使用者之间的 SAE 率在统计学上没有显著差异。
结论: 除了减少一个 MTX 臂的放射性关节损伤外,没有发现包括背景 GC 治疗的患者对疗效和安全性试验结果的影响。

Methotrexate

神经 抑制剂 治疗药物
概述  :  

本品作为一种叶酸还原酶抑制剂,主要抑制二氢叶酸还原酶而使二氢叶酸不能被还原成具有生理活性的四氢叶酸,从而使嘌呤核苷酸和嘧啶核苷酸的生物合成过程中一碳集团的转移作用受阻,导致DNA的生物合成明显受到抑制。此外,本品也有对胸腺核苷酸合成酶的抑制作用,但抑制RNA与蛋白质合成的作用则较弱。本品主要作用于细胞周期的S期,属细胞周期特异性药物,对G1/S期的细胞也有延缓作用,对G1期细胞的作用较弱。 用药指征 1. 适用于各种类型急性白血

methotrexate   英 [,meθə'trekseɪt; ,miːθə-]  美 [,mɛθə'trɛkset]

释义    n. 甲氨蝶呤,[药] 氨甲叶酸,[药] 氨甲蝶呤

例句    This is important, as people prescribed methotrexate are often advised to limit their alcohol intake to avoid possible liver problems. 这点很重要,因为根据规定,甲氨蝶呤服用过程中要限制酒精的摄入以避免可能引起的肝脏损伤。

请扫描右侧二维码,免费查看词汇专业知识背景